Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NARATRIPTAN vs SUMATRIPTAN AND NAPROXEN SODIUM
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Selective serotonin 5-HT1B/1D receptor agonist; binds to these receptors on intracranial blood vessels and trigeminal sensory neurons, causing vasoconstriction and inhibition of neuropeptide release, thereby reducing migraine-related inflammation and pain.
Sumatriptan is a selective 5-HT1B/1D receptor agonist, causing vasoconstriction of intracranial arteries and inhibiting trigeminal nerve transmission. Naproxen sodium is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis. The combination provides synergistic relief for migraine by targeting both neurogenic inflammation and vasodilation.
Acute treatment of migraine with or without aura in adults
Acute treatment of migraine with or without aura in adults,Off-label: Acute treatment of cluster headache (sumatriptan component)
2.5 mg orally at onset of migraine; may repeat after 4 hours if headache recurs, maximum 5 mg per day.
Sumatriptan 85 mg/naproxen sodium 500 mg orally at onset of migraine; maximum one tablet per 24 hours.
Terminal elimination half-life is approximately 5–6 hours (range 4–8 hours), supporting a twice-daily dosing interval for acute migraine treatment and allowing once-daily dosing for menstrual migraine prophylaxis.
Sumatriptan: 2.5 hours (range 2-4 hours); Naproxen: 12-17 hours (mean 14 hours). Clinical context: Sumatriptan half-life supports short dosing interval; Naproxen half-life allows twice-daily dosing for migraine prevention.
Hepatic via cytochrome P450 (CYP) enzymes, primarily CYP3A4, with minor contribution from other isoforms. Metabolites are inactive.
Sumatriptan is metabolized primarily by monoamine oxidase A (MAO-A) to an indoleacetic acid metabolite. Naproxen sodium is metabolized by hepatic CYP enzymes (CYP1A2, CYP2C9) and other pathways, with glucuronidation.
Renal: ~50% (metabolites and unchanged drug); Fecal: ~30%; Biliary: minor; unchanged naratriptan accounts for <10% of urinary recovery.
Sumatriptan: 57% renal (22% unchanged), 38% fecal; Naproxen: 95% renal (mostly as conjugated metabolites, <5% unchanged), <5% fecal.
~29% bound, primarily to albumin.
Sumatriptan: 14-21% (primarily albumin); Naproxen: >99% (albumin, extensively bound).
Approximately 2.4 L/kg (range 1.8–3.0 L/kg), consistent with extensive tissue distribution beyond plasma.
Sumatriptan: 2.4 L/kg (suggests extensive tissue distribution); Naproxen: 0.16 L/kg (confined primarily to plasma and synovial fluid).
Oral: 74% (range 63–95%); subcutaneous: ~100% (but not marketed).
Sumatriptan: Oral 15% (due to first-pass metabolism), subcutaneous 96%, intranasal 17%; Naproxen: Oral >95% (nearly complete).
No dose adjustment recommended; however, use with caution in severe renal impairment (Cr Cl <15 m L/min) due to limited data.
Contraindicated in severe renal impairment (Cr Cl <30 m L/min); no adjustment recommended for mild to moderate impairment.
Contraindicated in severe hepatic impairment (Child-Pugh class C). In mild to moderate impairment (Child-Pugh A or B), maximum dose is 2.5 mg per day; do not exceed single dose of 2.5 mg.
Contraindicated in severe hepatic impairment (Child-Pugh class C); not recommended in moderate impairment (Child-Pugh class B); no adjustment for mild (Child-Pugh class A).
Safety and efficacy not established in patients under 18 years; no approved pediatric dosing guidelines.
Not recommended for patients under 18 years due to safety and efficacy not established.
Use with caution due to potential for reduced hepatic and renal function; no specific dose adjustment recommended, but start at low end of dosing range (2.5 mg).
Not recommended in patients ≥65 years due to increased risk of adverse events; no specific dosing adjustments available.
Naratriptan is contraindicated in patients with ischemic heart disease or coronary artery vasospasm due to risk of myocardial ischemia/infarction and cerebrovascular events.
None
Cardiac events: risk of myocardial ischemia, infarction, and arrhythmias,Cerebrovascular events: stroke, subarachnoid hemorrhage,Serotonin syndrome: especially with concomitant serotonergic drugs,Medication overuse headache: chronic use can lead to daily headaches,Severe hepatic impairment: reduce dose or avoid,Severe renal impairment: contraindicated
Cardiovascular risk: Serious cardiovascular events including myocardial infarction, stroke, and coronary vasospasm, especially in patients with risk factors.,Gastrointestinal risk: NSAID-induced GI bleeding, ulceration, and perforation, particularly in elderly or those with prior GI history.,Hypertension: Elevation in blood pressure, including hypertensive crisis.,Serotonin syndrome: Risk when combined with other serotonergic drugs (e.g., SSRIs, MAOIs).,Renal toxicity: NSAIDs may impair renal function.,Anaphylaxis/allergic reactions: Immediate medical attention required.,Withdrawal headache: Overuse may lead to medication-overuse headache.
Ischemic heart disease (angina, history of MI, silent ischemia),Coronary artery vasospasm (Prinzmetal's angina),History of stroke or transient ischemic attack,Uncontrolled hypertension,Hemiplegic or basilar migraine,Severe hepatic impairment (Child-Pugh C),Severe renal impairment (Cr Cl <15 m L/min),Concurrent use of ergotamine derivatives or other 5-HT1 agonists within 24 hours,Hypersensitivity to naratriptan or any component
History of coronary artery disease, myocardial infarction, or ischemic heart disease,Coronary vasospasm (Prinzmetal's angina),Uncontrolled hypertension,Cerebrovascular disease (stroke or transient ischemic attack),Peripheral vascular disease,Hemiplegic or basilar migraine,Severe hepatic impairment,Third trimester of pregnancy,History of GI bleeding or perforation related to NSAID use,Active peptic ulcer disease,Concurrent use of MAO-A inhibitors or within 2 weeks of discontinuation,Hypersensitivity to sumatriptan, naproxen, or aspirin/other NSAIDs (including aspirin triad)
No significant food interactions. However, grapefruit juice may theoretically increase naratriptan exposure via CYP1A2 inhibition; avoid concurrent intake of large quantities. Alcohol may exacerbate migraine symptoms and should be avoided during an attack.
No specific food restrictions, but avoid alcohol due to increased GI bleeding risk. May take with or without food. Food may delay absorption slightly but does not affect efficacy.
FDA Pregnancy Category C. Animal studies show fetal toxicity (increased resorptions, skeletal anomalies) at maternotoxic doses. No adequate human studies. Avoid in first trimester unless benefit outweighs risk. Second/third trimester: limited data; use only if clearly needed.
Sumatriptan: Human data do not show increased risk of major birth defects overall, but limited data in first trimester; animal studies show embryo/fetal toxicity at high doses. Naproxen: NSAIDs should be avoided after 30 weeks gestation due to risk of premature closure of ductus arteriosus and oligohydramnios; avoid in first and second trimesters unless clearly needed due to potential association with cardiac defects and miscarriage.
Unknown if excreted in human milk; M/P ratio not established. Due to low molecular weight (335.46 g/mol), excretion is possible. Caution advised; monitor infant for adverse effects (e.g., drowsiness, diarrhea).
Sumatriptan: Excreted in breast milk in low amounts (M/P ratio 4.9); infant dose about 3.5% of maternal weight-adjusted dose; limited data show no adverse effects. Naproxen: Excreted in breast milk (M/P ratio 0.01-0.17); infant dose about 1-2% of maternal dose; use caution in premature infants or with prolonged use due to potential NSAID effects.
No specific pharmacokinetic data in pregnancy. Increased plasma volume and renal clearance in pregnancy may reduce drug exposure; however, lack of safety data precludes dose adjustments. Use lowest effective dose for shortest duration.
Sumatriptan: No dose adjustment recommended based on pharmacokinetic changes; however, consider lowest effective dose and avoid if possible first trimester. Naproxen: Avoid in pregnancy; if essential, use lowest effective dose for shortest duration. No pharmacokinetic data necessitating dose adjustment, but third trimester use is contraindicated.
Naratriptan has a longer half-life (~6 hours) and higher oral bioavailability (70%) compared to sumatriptan, making it suitable for patients with prolonged migraine attacks or those requiring sustained relief. It is contraindicated in patients with a history of ischemic heart disease, cerebrovascular disease, or uncontrolled hypertension due to vasoconstrictive effects. Use within 4 hours of migraine onset for optimal efficacy; do not use for prophylaxis. Monitor for serotonin syndrome when co-administered with other serotonergic drugs.
Combination tablet provides dual mechanism: sumatriptan (5-HT1B/1D agonist) and naproxen sodium (NSAID). Onset within 30 minutes. Maximum single dose: sumatriptan 85 mg/naproxen 500 mg. Risk of serotonin syndrome with other serotonergic drugs. Avoid in patients with ischemic heart disease, cerebrovascular disease, uncontrolled hypertension, or history of GI bleeding. Contraindicated within 24 hours of ergot alkaloids or other triptans. Renal dose adjustment necessary for Cr Cl <30 m L/min. Use lowest effective dose for shortest duration. Assess cardiovascular risk before prescribing. May cause drowsiness or dizziness.
Take naratriptan at the first sign of migraine headache; do not use to prevent migraines.,Do not exceed one tablet (2.5 mg) within 24 hours; do not take more than 2 tablets in any 24-hour period.,Seek emergency medical attention if you experience chest pain, shortness of breath, or sudden severe abdominal pain after taking this medication.,Inform your doctor if you have heart disease, high blood pressure, liver or kidney problems, or if you are pregnant or breastfeeding.,Avoid using naratriptan within 24 hours of other triptans or ergotamine-containing medications.
Take at the first sign of migraine; do not use to prevent migraines.,Do not exceed one tablet in 24 hours; wait at least 2 hours between doses.,Avoid alcohol, as it may increase risk of stomach bleeding.,Do not take with other NSAIDs (e.g., ibuprofen, aspirin) unless directed.,Seek emergency if chest pain, shortness of breath, sudden severe stomach pain, black/bloody stools, or signs of allergic reaction occur.,Avoid driving or operating machinery if drowsy or dizzy.,Notify doctor if you have heart disease, high blood pressure, liver/kidney disease, or are pregnant/nursing.
"Concurrent use of naratriptan, a serotonin 5-HT1B/1D receptor agonist, with dapiprazole, an alpha-1 adrenergic receptor antagonist, may lead to additive vasoconstrictive effects on coronary, cerebral, and peripheral vasculature. This synergy increases the risk of severe adverse events such as myocardial ischemia, hypertension, or cerebrovascular complications due to unopposed vasoconstriction from naratriptan and potential reflex sympathetic activation from dapiprazole's alpha blockade. Particularly in patients with underlying cardiovascular risk factors, this combination can precipitate hypertensive crises or ischemic events."
"Concomitant use of naratriptan, a serotonin 5-HT1B/1D receptor agonist, and clozapine, an atypical antipsychotic with potent 5-HT2A receptor antagonism, may lead to additive serotonergic effects, increasing the risk of serotonin syndrome. This potentially life-threatening condition is characterized by neuromuscular excitation, autonomic instability, and altered mental status. Patients, especially those on higher doses or with other serotonergic agents, should be closely monitored for symptoms such as hyperthermia, rigidity, myoclonus, and tachycardia."
"Concomitant use of naratriptan, a 5-HT1B/1D receptor agonist, with bromocriptine, a dopamine D2 receptor agonist and ergot alkaloid derivative, may result in additive vasoconstriction due to synergistic stimulation of serotonin and dopamine receptors on vascular smooth muscle. This can lead to an increased risk of hypertensive crises, coronary artery vasospasm, myocardial ischemia, or cerebral ischemia, particularly in patients with underlying cardiovascular disease. Additionally, both drugs can elevate serotonin levels centrally, potentially raising the risk of serotonin syndrome, characterized by agitation, hyperthermia, and neuromuscular abnormalities."
"Naproxen and meloxicam are both nonsteroidal anti-inflammatory drugs (NSAIDs) that inhibit cyclooxygenase (COX) enzymes, leading to decreased synthesis of prostaglandins, prostacyclin, and thromboxanes. Concomitant use increases the risk of dose-dependent adverse effects, particularly gastrointestinal ulceration, bleeding, and perforation, as well as renal impairment, due to additive inhibition of protective prostaglandins in the gut and kidney. Clinically, this combination may result in acute kidney injury, anemia from occult gastrointestinal bleeding, or life-threatening perforation, especially in elderly patients or those with pre-existing renal disease or peptic ulcer history."
"Bevantolol, a beta-1 selective adrenergic receptor antagonist, reduces cardiac output and suppresses renin release, thereby lowering blood pressure. Naproxen, a nonsteroidal anti-inflammatory drug (NSAID), inhibits cyclooxygenase (COX) enzymes, leading to decreased synthesis of vasodilatory prostaglandins and enhanced sodium and water retention. The net effect is an attenuation of bevantolol's antihypertensive efficacy, potentially resulting in elevated blood pressure and reduced cardiovascular protection."
"Betaxolol, a beta-1 selective adrenergic receptor antagonist, may reduce the antihypertensive efficacy of naproxen, a nonsteroidal anti-inflammatory drug (NSAID). Naproxen inhibits cyclooxygenase (COX) enzymes, leading to decreased synthesis of vasodilatory prostaglandins (e.g., prostacyclin) in the renal and vascular endothelium. This can result in sodium and fluid retention, increased systemic vascular resistance, and blunting of the blood pressure-lowering effects of beta-blockers like betaxolol, potentially compromising hypertension control."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NARATRIPTAN vs SUMATRIPTAN AND NAPROXEN SODIUM, answered by our medical review team.
NARATRIPTAN is a 5-HT1 Agonist that works by Selective serotonin 5-HT1B/1D receptor agonist; binds to these receptors on intracranial blood vessels and trigeminal sensory neurons, causing vasoconstriction and inhibition of neuropeptide release, thereby reducing migraine-related inflammation and pain.. SUMATRIPTAN AND NAPROXEN SODIUM is a 5-HT1 Agonist that works by Sumatriptan is a selective 5-HT1B/1D receptor agonist, causing vasoconstriction of intracranial arteries and inhibiting trigeminal nerve transmission. Naproxen sodium is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis. The combination provides synergistic relief for migraine by targeting both neurogenic inflammation and vasodilation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NARATRIPTAN and SUMATRIPTAN AND NAPROXEN SODIUM depend on the specific clinical indication. These are both 5-HT1 Agonist agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NARATRIPTAN is: 2.5 mg orally at onset of migraine; may repeat after 4 hours if headache recurs, maximum 5 mg per day.. The standard adult dose of SUMATRIPTAN AND NAPROXEN SODIUM is: Sumatriptan 85 mg/naproxen sodium 500 mg orally at onset of migraine; maximum one tablet per 24 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining NARATRIPTAN and SUMATRIPTAN AND NAPROXEN SODIUM. The risk or severity of adverse effects can be increased when Sumatriptan is combined with Naratriptan. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. NARATRIPTAN is classified as Category D/X. FDA Pregnancy Category C. Animal studies show fetal toxicity (increased resorptions, skeletal anomalies) at maternotoxic doses. No adequate human studies. Avoid in first trimester . SUMATRIPTAN AND NAPROXEN SODIUM is classified as Category D/X. Sumatriptan: Human data do not show increased risk of major birth defects overall, but limited data in first trimester; animal studies show embryo/fetal toxicity at high doses. Nap. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.